Malignant Hematology Clinical Investigator FacultyPhysician

Loma Linda University

Health (Loma Linda University Cancer Center, Loma Linda University

School of Medicine, and Loma Linda University Faculty Medical

Group), Division of Transplant and Cell Therapy (TCT)

/ Hematological Malignancies is looking to recruit for faculty

positions at open rank (Assistant / Associate / Professor) as clinical

investigators, including leadership opportunities to join our team.

We are seeking energetic faculty clinical

investigators who desire to develop an academic, clinical research

and patient-centered program, in close collaboration with

established basic and translational scientists at Loma Linda

University.

Successful candidates will have a

primarily clinical assignment, but will also be expected to

develop, conduct, and participate in clinical trials, other

collaborative research in Hematological malignancies. Leadership

opportunities are available based on candidate rank and experience.

Loma Linda University has a strong

collaborative, mentoring and supportive environment especially for

graduating fellows and junior faculty applicants.

Teaching responsibilities would involve oversight of

residents, fellows, and mid-level providers during ambulatory and

inpatient activities.

In addition to standard

therapies, TCT / Hem Malignancies Division is focused on the

development and implementation of novel therapies for Hematological

Malignancies including novel agents, small molecules inhibitors,

immune therapies (MoAbs, CAR-T, vaccine, and gene therapy) as well

as autologous and allogeneic hematopoietic stem-cell

transplantation.

Specific hematological

disease and treatment modality focus is optional and is based on

candidate preference.

This work is supported

by the Cancer Center Clinical Trials Unit, dedicated clinic space

and infusion centers, inpatient unit, a new cGMP and TCT

laboratory, FACT accredited TCT program in adult autologous and

allogeneic BMT and immune effector cell therapy, fully

characterized tumor samples repository and new state-of-the-art

Medical Center building opened in 2021, all on the Medical School

campus.

Loma Linda University was established

in 1905. Loma Linda University Medical Center is the major and only

Academic Medical Center in the Inland Empire in Southern California

that provides Transplant and Cell therapy.

Qualification requirements include MD (or equivalent), completion

of fellowships in Hematology and / or Medical Oncology, and

Hematology or Medical Oncology board eligible or certified.

Comprehensive salary, benefits, and a

competitive package will be provided, and academic appointment will

be commensurate with experience and qualifications. Administrative

and research support including staff, resources and infrastructure

will be provided.

The campus is located within

driving distance from Los Angeles, beach cities and San Diego.

Interested candidates should submit inquiries

to Division Head : Hisham Abdel-Azim, MD ( habdelazim@llu.edu) .

LLHU values diversity and is committed to

equal opportunity in employment.

Compensation & Benefits

The compensation range listed is for

starting base compensation only and is adjusted based upon years of

experience and / or faculty rank : $200,000 – $500,000. This amount

does not include variable compensation or extra productivity and is

subject to the individual department compensation plans. More

information on compensation is discussed with the departments

during the recruitment process.

Our

benefits include :

Generous Retirement Contribution

Comprehensive Medical / Dental Coverage

Competitive Vacation & Sick Days

CME

Days and Funds

Relocation Assistance (if

applicable)

Paid Malpractice Insurance

• Paid Life Insurance

Loan Repayment / State & Federal (If eligible)

For more information on Loan

Forgiveness, please click on the link below :

We are a

California Employer - Please note that a California residency is

required upon start date.

This opportunity is

not eligible for a Conrad 30 waiver.